A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults

被引:47
作者
Jimenez-Cruz, F
Jasovich, A
Cajigas, J
Jiang, Q
Imbeault, D
Woods, GL
Gesser, RM
机构
[1] Hosp Carlos Bocalandro, Buenos Aires, DF, Argentina
[2] Hosp Univ La Fe Valencia, Valencia, Spain
[3] Hosp Millitar Cent, Bogota, Colombia
[4] Merck Res Labs, W Point, PA USA
关键词
D O I
10.1016/S0090-4295(02)01664-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To compare the efficacy and safety of ertapenem, a new once-daily parenteral beta-lactam, with that of ceftriaxone for the initial empiric treatment of adults with complicated urinary tract infections (cUTIs). Methods. In a multicenter, prospective, double-blind study, patients with cUTIs were stratified as to whether they had acute pyelonephritis or other cUTIs (without pyelonephritis) and randomized to receive ertapenem, I g once a day, or ceftriaxone, I g once a day. After 3 days, patients with a satisfactory clinical response could be switched to an oral antimicrobial agent. Results. Of 258 randomized patients, 97 (55.4%) in the ertapenem group and 53 (63.9%) in the ceftriaxone group were evaluated microbiologically. Almost all patients in each treatment group were switched to oral therapy. The mean duration of therapy was similar in both treatment groups: parenteral, approximately 4 days; total, approximately 13 days. The most common pathogen was Escherichia coli. At the primary efficacy endpoint, 5 to 9 days after treatment, 85.6% of patients who received ertapenem and 84.9% who received ceftriaxone had a favorable microbiologic response, indicating that the two treatment groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. Conclusions. In this study, ertapenem was as effective as ceftriaxone for the initial treatment of cUTI in adults, was generally well tolerated, and had a similar safety profile. (C) 2002, Elsevier Science Inc.
引用
收藏
页码:16 / 22
页数:7
相关论文
共 17 条
[1]   SOME METHODS FOR STRENGTHENING THE COMMON X2 TESTS [J].
COCHRAN, WG .
BIOMETRICS, 1954, 10 (04) :417-451
[2]  
COX CE, 1989, AM J MED S5A, V87, P157
[3]   USE OF CIPROFLOXACIN VERSUS USE OF AMINOGLYCOSIDES FOR THERAPY OF COMPLICATED URINARY-TRACT INFECTION - PROSPECTIVE, RANDOMIZED CLINICAL AND PHARMACOKINETIC STUDY [J].
FANG, GD ;
BRENNEN, C ;
WAGENER, M ;
SWANSON, D ;
HILF, M ;
ZADECKY, L ;
DEVINE, J ;
YU, VL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) :1849-1855
[4]  
FRIMAN G, 1989, INFECTION, V5, P284
[5]   In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1915-1918
[6]   Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women [J].
Gupta, K ;
Scholes, U ;
Stamm, WE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (08) :736-738
[7]   Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY Antimicrobial Surveillance Program, 1997 [J].
Jones, RN ;
Kugler, KC ;
Pfaller, MA ;
Winokur, PL .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 35 (01) :55-63
[8]   A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection [J].
Klimberg, IW ;
Cox, CE ;
Fowler, CL ;
King, W ;
Kim, SS ;
Callery-D'Amico, S .
UROLOGY, 1998, 51 (04) :610-615
[9]   In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia [J].
Livermore, DM ;
Carter, MW ;
Bagel, S ;
Wiedemann, B ;
Baquero, F ;
Loza, E ;
Endtz, HP ;
van den Braak, N ;
Fernandes, CJ ;
Fernandes, L ;
Frimodt-Moller, N ;
Rasmussen, LS ;
Giamarellou, H ;
Giamarellos-Bourboulis, E ;
Jarlier, V ;
Nguyen, J ;
Nord, CE ;
Struelens, MJ ;
Nonhoff, C ;
Turnidge, J ;
Bell, J ;
Zbinden, R ;
Pfister, S ;
Mixson, L ;
Shungu, DL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1860-1867
[10]  
MAJUMDAR A, 2001, 41 INT C ANT AG CHEM, P22